[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ratio Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100652372","early-phase-1-a-study-of-the-pharmacokinetics-biodistribution-and-dosimetry-of-granzyme-b-targeted-cu-64-labeled-pet-radiotracers-in-adult-healthy-volunteers-100652372",false,"NCT07774650","A Study of the Pharmacokinetics, Biodistribution and Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Adult Healthy Volunteers","A Phase 0 Study of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers","Inclusion Criteria:\n\n1. Adult male or female participants 18-60 years of age judged to be in good health by the Investigator\n2. No clinically significant laboratory abnormalities; all tests of liver and kidney function within normal limits\n3. Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the ICF and this protocol\n4. Female participants of childbearing potential and male participants who are fertile and have female partners of childbearing potential must agree to use adequate birth control throughout the study to the conclusion of follow-up.\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding female participants (female participants of childbearing potential must have negative pregnancy tests at Screening and pre-dose Day 0)\n2. Inadequate venous access (at least two distinct access sites allowing for separate test agent administration and PK blood sampling are required)\n3. Inability or unwillingness to undergo serial PET\u002FCT imaging\n4. Active infection or malignancy\n5. Known or suspected inflammatory, autoimmune or fibrotic disease\n6. Major surgery or other intensive medical treatment in the 3 months prior to planned study injection, as assessed by the investigator\n7. Received a radioisotope within 7 physical half-lives of that radioisotope prior to planned study injection\n8. Known allergy\u002Fhypersensitivity to PET\u002FCT tracers or compounds similar to GzmB-Targeted Compounds\n9. Concurrent participation in a clinical trial of investigational product(s)\n10. Participation in other research protocols or clinical care where there was radiation exposure such that the exposure from the last year, in addition to the radiation exposure expected from participation in this clinical study, exceeds the effective dose of 50 mSv, which would be above the acceptable annual limit established by US federal guidelines\n11. Significant intercurrent illness or psychiatric illness\u002Fsocial situation that could place the participant at undue risk during study participation, significantly alter study outcomes, or affect participant compliance with study requirements for dosing and evaluation, as determined by the investigator",true,"ALL","18 Years","60 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","This is an exploratory clinical study of copper-64 \\[Cu-64\\]-labeled granzyme B (GzmB)-targeted compounds for PET\u002FCT imaging. The goal is to determine how GzmB-Targeted \\[Cu-64\\]-labeled compounds are distributed in the body by assessing PET\u002FCT images and blood samples, and to assess the safety profile after a single intravenous dose.\n\nUp to 6 healthy volunteers (3 female, 3 male) will receive one injection of a GzmB-targeted \\[Cu-64\\]-labeled compound, then undergo multiple whole-body PET\u002FCT scans, blood and urine tests over about 24 hours, and a follow-up phone call around Day 7. Up to 2 GzmB-Targeted \\[Cu-64\\]-labeled compounds may be assessed (i.e. maximum of 12 healthy volunteers in total in the study).\n\nResearchers will look at the blood activity of GzmB-Targeted \\[Cu-64\\]-labeled compound and the organ distribution and movement of the product in the body. They will also evaluate any changes in physical examination assessments, vital signs, ECG, and clinical laboratory measurements from pre-administration to post-administration.",[28],"Healthy Volunteer","RECRUITING","2026-08-17",{"date":32,"type":33},"2026-08-19","ACTUAL",{"date":35,"type":33},"2026-07-08",{"date":37,"type":22},"2026-12",{"name":39,"class":40},"Ratio Therapeutics, Inc.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100604980","phase-1-actinium-therapy-for-late-stage-aggressive-sarcomas-100604980","NCT07156565","Actinium Therapy for Late-stage Aggressive Sarcomas","A Seamless Phase 1\u002F2 Open-label Study to Evaluate the Safety, Determine the Maximum Tolerated Dose of Administered Activity, and Evaluate the Efficacy of the Therapeutic Radiopharmaceutical [Ac 225]-RTX-2358 in the Treatment of Relapsed or Refractory Sarcoma","ATLAS","Inclusion Criteria:\n\n* 18 years of age or older.\n* History of relapse and refractory soft tissue sarcoma.\n\n  1. Histological confirmation of sarcoma at any point since diagnosis\n  2. At least 1 prior treatment regimen\n* Measurable disease as per RECIST (v1.1) for soft tissue sarcoma that is also positive on FAPi PET\u002FCT or PET\u002FMRI scan.\n* ECOG performance status of 0 or 1.\n* Adequate Organ reserve and renal function as evidenced by:\n\n  1. Neutrophil count ≥ 1200 µL without granulocyte colony stimulating factor\n  2. Platelet count ≥ 100,000 µL\n  3. Hemoglobin ≥ 8 g\u002FdL\n  4. Total bilirubin level ≤ 1.5 × upper limit of normal (ULN).\n  5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN.\n  6. Calculated creatinine clearance ≥ 60 mL\u002Fmin. 6. Coagulation parameters (prothrombin time, international normalized ratio and activated partial thromboplastin time) ≤ 1.5 × ULN 7. All patients (males and females of childbearing potential) must agree to practice 2 forms of highly effective contraceptive precautions to prevent pregnancy from the time consent is signed and throughout the trial.\n\n     8\\. The patient or the patient's legal representative must be willing and able to provide written informed consent.\n\n     Exclusion Criteria:\n* History of whole pelvic irradiation.\n* History of radioligand therapy.\n* Treatment within 14 days prior to first administration with:\n\n  1. Palliative surgery or external beam radiation.\n  2. Approved anticancer therapy including chemotherapy or immunotherapy.\n  3. Any investigational therapy.\n  4. Any major surgery (e.g., requiring general anesthesia).\n* Patients who are scheduled for external beam radiation therapy or radioligand therapy during the study period.\n* Congestive heart failure \\> Class II New York Heart Association Functional Classification, current pericarditis, myocardial infarction within 6 months, or symptomatic coronary artery disease.\n* Patients with uncontrollable incontinence.\n* Unstable or clinically significant concurrent medical condition that would, in the opinion of the Investigator, jeopardize the safety of a patient and\u002For their compliance with the protocol.\n* Active infection requiring systemic antibacterial\u002Fantibiotic, antifungal, or antiviral therapy. Chronic antiviral therapy for stable viral disease can be included.\n* History of active fibrotic condition.\n* Any active malignancy other than sarcoma that requires treatment.\n* Stable brain metastasis is allowed but documented untreated metastases to brain or meninges are excluded.\n* Currently pregnant or lactating.\n* Known allergy to any of the study drugs or their excipients.\n* Inability or unwillingness to comply with any of the required imaging studies or study assessments.",{"count":51,"type":22},30,[53],"PHASE1","The goal of this clinical trial is to learn about the safety of drug \\[Ac225\\]RTX-2358 and the diagnostic imaging agent \\[Cu64\\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \\[Ac225\\]RTX-2358 drug is effective in treating advanced sarcoma.\n\nThe main questions the study aims to answer in Phase\u002FPart 1 of the trial are:\n\n* Is \\[Ac225\\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients.\n* What is the most tolerable dose of \\[Ac225\\]RTX-2358\n* Does the treatment show effectiveness on advanced sarcoma\n\nParticipants will:\n\n* Take drug \\[Ac225\\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months\n* Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests.\n* For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests\n* Remain in long term follow-up for a period of four additional years",[56],"Advanced Soft Tissue Sarcoma",[58,59,60,61,62,63,64],"Radioligand Therapy","Sarcoma","Relapsed or refractory sarcoma","Soft tissue sarcoma","Radiopharmaceuticals","Theranostics","advanced soft tissue sarcoma","2026-07-14",{"date":67,"type":33},"2026-07-15",{"date":69,"type":33},"2025-11-12",{"date":71,"type":22},"2032-01",{"name":39,"class":40},6,""]